A nuclear medical radioisotope production facility being constructed on Janesville’s south side gets a major investment. SHINE Medical Technologies has closed on a $50-million financing deal with global investment firm Oaktree Capital Management. The financing deal is the largest SHINE has announced since last November when it announced landing a $150-million deal with health care investment firm Deerfield Management. SHINE intends to be producing the radioisotope medical imaging material Molybdenum-99 within three-years.
